ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,579.06
      -0.97%
      US Tech 100
      19,646.00
      -2.35%
      Dow Jones
      39,792.94
      0.18%
      Brent Oil
      84.95
      -0.12%
      Bitcoin
      57,729.96
      -0.05%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Keros Therapeutics Inc (KROS)

      7. Keros Therapeutics Inc (KROS) News

      KROS

      Keros Therapeutics (KROS)

      Keros Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:KROS
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      12/13/20218:00AMGlobeNewswire Inc.Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in ChinaNASDAQ:KROSKeros Therapeutics Inc
      12/03/20215:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      11/22/20218:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
      11/15/20218:05AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      11/15/20218:00AMGlobeNewswire Inc.Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific SessionsNASDAQ:KROSKeros Therapeutics Inc
      11/11/20218:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the Jefferies Virtual London Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
      11/08/20218:00AMGlobeNewswire Inc.Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific SessionsNASDAQ:KROSKeros Therapeutics Inc
      11/05/20215:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      11/04/20219:25AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      11/04/20219:13AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KROSKeros Therapeutics Inc
      11/04/20219:01AMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
      11/04/20219:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
      11/03/20217:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      10/04/20218:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      10/04/20218:00AMGlobeNewswire Inc.Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual MeetingNASDAQ:KROSKeros Therapeutics Inc
      09/29/20214:40PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      09/09/20214:03PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      09/02/20218:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      09/02/20218:00AMGlobeNewswire Inc.Keros Therapeutics to Participate in Two Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
      08/18/20215:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      08/11/20214:55PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:KROSKeros Therapeutics Inc
      08/05/20214:10PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KROSKeros Therapeutics Inc
      08/05/20214:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      08/05/20214:01PMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
      08/02/20219:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KROSKeros Therapeutics Inc
      08/02/20219:00AMGlobeNewswire Inc.Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical OfficerNASDAQ:KROSKeros Therapeutics Inc
      07/06/20216:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      06/25/20216:30PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KROSKeros Therapeutics Inc
      06/22/20214:01PMGlobeNewswire Inc.Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodys...NASDAQ:KROSKeros Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:KROS